Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-03-22

Clinical Trial Update: Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating serelaxin versus standard of care in acute heart failure was terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Serelaxin (serelaxin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acute Heart Failure (AHF) | Phase 3 | Status: TERMINATED | Results posted: 2019-03-22